Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
In what is believed to be the most comprehensive molecular characterization to date of the most common type of head and neck cancer, researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.
Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center.
A recent international observational study provides important data on the safety of head and neck cancer surgery during the COVID-19 pandemic.
The use of telemedicine services has shown to be exceptionally effective in meeting the health care needs of patients throughout the COVID-19 pandemic.
University of Cincinnati researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't.
The Affordable Care Act's Medicaid expansion for low-income people appears to lead to earlier diagnosis of colon cancer, enhanced access to care, and improved surgical care for patients with this common cancer, researchers report in a new study.
A clinical trial at the University of Arizona Health Sciences designed to study the safety and effectiveness of a personalized cancer vaccine in combination with the immunotherapy drug Pembrolizumab will expand its cohort after promising preliminary data was presented at the annual meeting of the Society for the Immunotherapy of Cancer.
Summit Biolabs, Inc., an early-stage molecular diagnostics company specializing in saliva-based testing for COVID-19 and head & neck cancer, and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus announced today a broad strategic collaboration involving research, development and commercialization of saliva liquid-biopsy tests for early cancer detection and diagnosis of COVID-19 and other viral contagions.
The global quest to use a person's breath analysis for rapid, inexpensive and accurate early-stage testing for cancer and other diseases has taken a leap forward.
A single-center observational study of more than 1,000 oncological examinations has demonstrated that positron emission tomography/magnetic resonance imaging (PET/MRI) facilitates cancer staging as well as PET/computed tomography (PET/CT) and improves lesion detectability in select cancers, potentially helping to promote fast, efficient local and whole-body staging in one step.
Researchers at Flinders University are expanding work on a promising blood test model to help predict or diagnose head and neck cancer, a difficult cancer to pick up early and treat.
An ear, nose, and throat doctor has invented a simple mask design that significantly improves safety during aerosol-generating procedures of the head and neck.
Updated clinical practice guidelines for managing mucositis, a very common and often debilitating complication of cancer therapy, was recently published in the journal Cancer.
Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma.
Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, and squamous cell carcinomas (HNSCC) account for the majority of these cases.
Researchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.
Blocking a newly identified "immune memory checkpoint" in immune cells could improve immunotherapy and help prevent cancers from recurring, according to new findings in mice and human samples by researchers at the UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine.
Scientists have engineered natural killer immune cells that not only kill head and neck tumor cells in mice but also reduce the immune-suppressing myeloid cells that allow tumors to evade the immune response, according to a new study in eLife.
Patients who were unexpectedly hospitalized for dehydration, fever or other ailments while undergoing radiation treatment for head and neck cancers were at a higher risk for less favorable outcomes, a new study from Roswell Park Comprehensive Cancer Center reports.
The Damon Runyon Cancer Research Foundation has named four new Damon Runyon Clinical Investigators.